U.S. Markets

Johnson & Johnson (JNJ) announces US FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more